Compare Entegris Inc (ENTG) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs GSK plc — how do they compare? Entegris Inc trades at $165.79 (market cap $24.78B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.7× Entegris Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and GSK plc for 93 Days on average.
| ENTG | GSK | |
|---|---|---|
Market Cap | $24.78B | $91.88B |
Volume | 2,648,320 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $184.00 | $61.18 |
52-Week Low | $68.80 | $43.24 |
Typical Hold Time | 41 Days | 93 Days |
Enterprise Value | $27.99B | $111.88B |
Dividend Yield | 0.25% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $162.19, down 2.48% today, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 29, 2026. Revenue for 2025 was $3.20B, with a net income margin of 7.37%. Analyst consensus is strongly bullish, with a price target of $182.43, indicating a 12.5% upside. Recent news highlights strong AI-driven semiconductor demand and institutional buying interest.
The outlook for ENTG is positive, supported by robust earnings performance and growing demand in the semiconductor sector. Key opportunities include expansion in AI-related markets and operational efficiency gains. Risks involve high valuation multiples, competitive pressures, and sensitivity to semiconductor industry cycles. Investors should weigh the strong analyst support against potential market volatility and execution challenges.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
